Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology July 25, 2011
Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease. July 16, 2011
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice. July 16, 2011
Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease July 15, 2011
Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well July 6, 2011
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders May 11, 2011
Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease April 20, 2011
